Shots: The P-II DESTINY-Breast01 study involves assessing of trastuzumab deruxtecan in 184 patients with HER2+ unresectable/ mBC prior treated with trastuzumab emtansine across 100 sites globally The P-II DESTINY- Breast01 […]readmore
Tags : DESTINY-Breast01
Shots: The P-II DESTINY-Breast01 study involves assessing of Trastuzumab Deruxtecan (DS-8201) in 253 patients with HER2+ unresectable and/or m-breast cancer prior treated with trastuzumab emtansine The P-II DESTINY-Breast01 study result: […]readmore